Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Strengthened Cash Position to Support Ongoing R&D and Commercial Activities; Reported $107 Million in Cash at the End of the Third Quarter Expanded Novel Bispecific Antibody Portfolio Through...
-
New Preclinical Data Show APVO436 Demonstrates Rapid and Significant Reduction in Skeletal Tumor Burden in Mice with Well-Established and Disseminated Tumors SEATTLE, Oct. 30, 2017 (GLOBE NEWSWIRE)...
-
ALG.APV-527 Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications LUND, Sweden and SEATTLE, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Alligator Bioscience...
-
New Autoimmune Candidate APVO210 Demonstrates Targeted Cytokine Delivery for Application in Various Autoimmune and Inflammatory Diseases SEATTLE, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aptevo...
-
SEATTLE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced...
-
SEATTLE, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced...
-
Sharpens Focus on Innovative ADAPTIR® Bispecific Antibody Platform and IXINITY® Commercial Asset Strengthens Cash Position to Advance R&D and Commercial Strategy SEATTLE, Sept. 28, 2017 (GLOBE...
-
Provides Significant Non-Dilutive Funding to Execute R&D Strategy Sharpens Focus on Proprietary ADAPTIR™ Protein Therapeutic Platform Retains IXINITY® Commercial Asset SEATTLE, Aug. 31, 2017 ...
-
Aptevo Regains Worldwide Rights to Novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414 Preliminary Phase I Data Show Markedly Lower Anti-Drug Antibody Titers Demonstrating Effectiveness...
-
Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications SEATTLE and LUND, Sweden, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc....